6 515

Cited 0 times in

Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients

 Kim, Gun Min  ;  Kim, Young Sam  ;  Kang, Young Ae  ;  Jeong, Jae-Heon  ;  Kim, Sun Mi  ;  Hong, Yun Kyoung  ;  Sung, Ji Hee  ;  Lim, Seung Taek  ;  Kim, Joo Hang  ;  Kim, Se Kyu  ;  Cho, Byoung Chul 
 JOURNAL OF THORACIC ONCOLOGY, Vol.7(4) : 731-736, 2012 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives* ; Camptothecin/therapeutic use ; Carcinoma, Small Cell/drug therapy* ; Carcinoma, Small Cell/mortality ; Disease-Free Survival ; Female ; Humans ; Lung Neoplasms/drug therapy* ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy* ; Retrospective Studies ; Topoisomerase I Inhibitors/therapeutic use*
Belotecan ; Relapsed ; Refractory ; Small cell lung cancer
INTRODUCTION: Belotecan (Camtobell, CKD602) is a new camptothecin-derivative antitumor agent that belongs to the topoisomerase inhibitors. The aim of this study was to evaluate the efficacy and safety of belotecan monotherapy as a second-line therapy in patients with relapsed or refractory small cell lung cancer (SCLC).

METHODS: Between June 2008 and August 2011, a total of 50 patients with relapsed or refractory SCLC were treated with belotecan 0.5 mg/m for 5 consecutive days, every 3 weeks. We evaluated the overall response rate (ORR), the progression-free survival (PFS), and the overall survival (OS), and toxicity according to sensitivity to initial chemotherapy.

RESULTS: The median age was 66 years (range, 43-84 years) and Eastern Cooperative Oncology Group performance was 0 or 1 in 34 patients (68%) and 2 in 16 patients (32%). Twenty patients (40%) had sensitive relapse and 30 patients (60%) had refractory disease. The ORR, PFS, and OS for sensitive patients were 20% (95% confidence interval [CI], 8-40), 2.8 months (95% CI, 0.53-5.06), and 6.5 months (95% CI, 1.58-11.42), respectively. In the refractory group, the ORR, PFS, and OS were 10% (95% CI, 1-21), 1.5 months (95% CI, 1.25-1.75), and 4.0 months (95% CI, 3.40-4.60), respectively. Most commonly reported grade-3 or -4 adverse events included neutropenia (54%), thrombocytopenia (38%), and anemia (32%).

CONCLUSION: Belotecan showed modest activity with an acceptable safety profile as a second-line therapy in patients with relapsed or refractory SCLC.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원) > 1. Journal Papers
Yonsei Authors
Kang, Young Ae(강영애) ORCID logo https://orcid.org/0000-0002-7783-5271
Kim, Gun Min(김건민) ORCID logo https://orcid.org/0000-0001-9167-8682
Kim, Sun Mi(김선미)
Kim, Se Kyu(김세규)
Kim, Young Sam(김영삼) ORCID logo https://orcid.org/0000-0001-9656-8482
Kim, Joo Hang(김주항)
Lim, Seung Taek(임승택)
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.